Russ Conroy

Sunil Singhal, MD, discussed how fluorescence imaging via abenacianine helps surgeons visualize tumors missed during lung cancer surgery.

Two teams of multiple myeloma experts debate the use of early CAR T-cell therapies and bispecific antibodies based on key trial data and various hot topics.

Bispecific antibodies “will form the standard backbone agents for multiple myeloma therapies,” according to Hans Lee, MD.

A nurse practitioner, clinical social worker, and patient discuss navigating treatment-related concerns and psychosocial considerations in multiple myeloma.

Data from the SAFFRON trial may represent a critical advance in the management of EGFR-mutated NSCLC with MET-driven resistance.

Data presented at the 2026 AACR Annual Meeting demonstrated the promise of blood-based lung cancer detection via SimpleScreen Lung.

Data from the phase 3 EXCALIBER-RRMM trial support the FDA accelerated approval of iberdomide plus daratumumab and hyaluronidase and dexamethasone in this multiple myeloma population.

Ajay K. Nooka, MD, MPH, FACP, discusses how results from the MonumenTAL-6 trial build upon prior studies assessing bispecific antibodies in multiple myeloma.

The approval status of lurbinectedin as first-line care for those with small cell lung cancer will not be affected following results from the LAGOON trial.

Phase 1 trial data for cevostamab in multiple myeloma validate fixed-duration therapy as a “good concept,” according to Adam D. Cohen, MD.

Clinicians “still don’t have the answer” on true toxicity thresholds, says Tiba Al Sagheer, PharmD, BCOP, BCACP, on CAR T-cell toxicity management.

Approval of the SimpleScreen CRC test may increase earlier detection of colorectal cancer and improve patient outcomes.

Experts discuss how to properly select first-line regimens for EGFR-mutated NSCLC in the context of different clinical scenarios.

The world of cellular therapy is “still ever-expanding” as novel constructs continue to emerge, according to Megan Melody, MD.

Mature overall survival data from the INSIGHT-003 trial compare favorably with historical benchmarks in frontline NSCLC therapy.

The FDA has assigned a Prescription Drug User Fee Act date of May 13, 2027, for the mezigdomide regimen in relapsed/refractory multiple myeloma.

Data from studies including the IRAKLIA trial support the approval of subcutaneous isatuximab plus standard of care in multiple myeloma.

Data from the phase 3 Precision-T trial support the FDA approval of allogeneic regulatory T-cell–based immunotherapy.

Two teams of lung cancer experts face off to determine the optimal first-line treatment regimen in EGFR-mutated metastatic NSCLC.

Investigators will share detailed results from the phase 3 SigVie-002 trial assessing sigvotatug vedotin in NSCLC at a future medical meeting.

Data from the SPEARHEAD-1 study support the full FDA approval of afami-cel in this synovial sarcoma population.

This year’s EHA Congress saw potential advances across multiple myeloma, leukemia, lymphoma, and other hematologic malignancy populations.

Data from a phase 2 trial support further clinical development of AK117 in previously untreated acute myeloid leukemia.

Data from a phase 1/2 trial show durable disease control with belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.

Phase 1 data support arlo-cel as a potentially effective early-line treatment option for those with relapsed/refractory multiple myeloma.

MRD responses appeared to be more favorable with the use of blinatumomab among pediatric patients with high-risk B-cell acute lymphoblastic leukemia.

Data from the MAXILUS study affirm the importance of early treatment initiation among those with lower-risk myelodysplastic syndrome.

High rates of MRD negativity were observed with a combination of carfilzomib, lenalidomide, daratumumab, and dexamethasone in the ASCENT trial.

Investigators observed no new safety signals with lurbinectedin alone or in combination with irinotecan in the phase 3 LAGOON trial.

Findings from the ASC4FIRST trial show that asciminib is meeting high expectations as a frontline therapy in chronic myeloid leukemia in chronic phase.